# Lunit: a large clinic network is an implementation opportunity, not an installed base The Salud Digna agreement combines imaging software delivery with data access and regional research. Canonical: https://kgcf.dsmlholdings.com/insights/lunit-salud-digna-imaging-agreement/ Published: 2026-10-08 Author: [DSML Holdings LLC](https://www.dsmlholdings.com/) Company: Lunit Event: 2024-11-27 Issuer's dated announcement of the direct imaging and research partnership, not a claim that every network clinic was already deployed. ## Reported metrics - Reported counterparty network: 230+ clinics. Network size in November 2024, not verified installed, invoiced or collected Lunit sites.. [Source 1](https://www.prnewswire.com/news-releases/lunit-inks-partnership-with-salud-digna-to-advance-ai-in-medical-imaging-302316214.html) - Consolidated cash and cash equivalents: KRW 14.1106bn. December 31, 2025 balance, rounded from KRW 14,110,597,196; not Salud Digna cash or an October 2026 balance.. [Source 2](https://kind.krx.co.kr/external/2026/03/23/002296/20260323009649/11011.htm) ## Reported evidence On November 27, 2024, Lunit announced an agreement to deliver chest-X-ray and mammography AI to Salud Digna's network of over 230 clinics in Mexico and Central America. The issuer also described access to millions of deidentified images and joint research. The network size is potential delivery scope, not a reported count of live paying installations. Lunit's March 23, 2026 annual filing supplies later consolidated financial context; it does not separately verify collections or the number of deployed Salud Digna sites. ## Investment interpretation This is a distribution and data-quality opportunity in a specific healthcare network. The Korean developer can potentially lower acquisition costs by working through a large operator, but one central agreement still requires local implementation and sustained use. The economic assessment should distinguish network reach, active installations, billable examinations and cash collection. Data access adds another asset only if its lawful and practical usefulness is established. ## Economic assessment Central contracting can reduce sales effort per clinic while introducing concentration in one payer and implementation organization. Pricing may be per site, examination or another contractual basis; it is not disclosed in the release. Deployment expenses can precede usage receipts, and data preparation can consume resources independently of software sales. Company-level cash should not be attributed to this contract, but it is relevant to whether the issuer can finance expansion before project receipts become dependable. ## A Network Still Requires Site Work A network agreement can standardize procurement and provide a route into many facilities. It does not make image systems, connectivity and clinical practices identical across those facilities. Each site may need interfaces, user provisioning, staff preparation and evidence that the workflow functions reliably. The public network count is therefore a scope indicator, not a software adoption denominator. Converting it directly into subscription revenue would omit the implementation sequence. The economically useful progression is contracted scope, technically connected sites, active use, billable use and collected receipts. These states may advance at different speeds. A clinic can be connected but use the software infrequently, while a busy site can produce far more examinations than a nominally similar site. The company should be assessed on actual operating intensity and renewal behavior, not simply on how many locations belong to the counterparty. 1. [Lunit / issuer-distributed Salud Digna agreement announcement](https://www.prnewswire.com/news-releases/lunit-inks-partnership-with-salud-digna-to-advance-ai-in-medical-imaging-302316214.html) ## Images Need Permission And Labels Deidentified images can help assess performance in local populations and imaging environments. Their value depends on permitted uses, reliable clinical labels, representative sampling and practical accessibility. Millions of files without those features may require extensive preparation before they improve a model. The announcement does not give a fixed data volume delivered or establish unrestricted ownership, so neither should be inserted into the valuation. A joint research arrangement also needs rules for publication, derivative models and cross-border processing. Deidentification should not be assumed to remove every governance obligation. The Korean developer's ability to reuse learning with other customers could be broader or narrower than its permission to analyze this dataset. These rights should be documented separately from the commercial software order, particularly if the model improvements are used to justify financing further geographic expansion. 1. [Lunit / issuer-distributed Salud Digna agreement announcement](https://www.prnewswire.com/news-releases/lunit-inks-partnership-with-salud-digna-to-advance-ai-in-medical-imaging-302316214.html) ## Regional Fit Is An Operating Asset The proposed Latin American adaptation is economically relevant because successful deployment depends on the customer environment, not just the algorithm's original benchmark. Image acquisition, disease prevalence and workflow can influence performance and review burden. A locally useful tool can strengthen retention and reduce repeated sales effort. The release establishes an intention to pursue such work, not a completed clinical validation or a measured improvement in care outcomes. For a network operator, the value may arise from prioritization, staff productivity or consistency of screening support. The payer may capture much of that benefit while negotiating a lower per-examination fee. A developer needs enough contribution to fund maintenance and continued validation after initial rollout. This makes the relationship a test of both usefulness and pricing discipline. Large potential examination volumes are attractive only when the cost to serve and contractual receipt basis remain coherent. 1. [Lunit / issuer-distributed Salud Digna agreement announcement](https://www.prnewswire.com/news-releases/lunit-inks-partnership-with-salud-digna-to-advance-ai-in-medical-imaging-302316214.html) ## Concentrated Access And Collection A central buyer can offer a more efficient route to scale, but its payment practices and implementation decisions become consequential. Acceptance milestones, minimum volumes, renewal terms and cancellation rights determine whether the arrangement supports recurring receipts. None of those should be inferred from the network's annual patient count. Economic exposure can be concentrated even where the physical deployment spans many clinics. The later annual filing shows why company cash and contract economics need separate attention. A cash balance on one reporting date is not a permanent liquidity reserve, and consolidated resources serve more than this network project. Diligence should connect rollout spending to collection schedules without dividing year-end cash by an assumed constant burn rate and calling the quotient guaranteed runway. A slower rollout may conserve deployment costs but postpone receipts; the correct choice depends on actual terms and available funding. 2. [Lunit / complete FY2025 annual filing, consolidated financial context](https://kind.krx.co.kr/external/2026/03/23/002296/20260323009649/11011.htm) ## China - DSML comparison Chinese imaging deployments provide a scale comparison, but no Chinese order arises from this agreement. ## Japan - DSML comparison Japanese hospital integration offers a comparison for workflow costs and validation, not a reported Salud Digna connection. ## Other Asia - Reported connection Lunit's Korean development base is the Asian connection. No broader Asian clinic rollout is established here. ## United States - DSML comparison Mexico and Central America are not US deployments. US clearance or reimbursement should not be inferred from this Latin American contract. ## Europe - DSML comparison European data and medical-device requirements offer a governance comparison; the announced customer network is elsewhere. ## Counterpoint One network relationship can provide more efficient distribution and more relevant validation data than many disconnected pilot projects. The opportunity is substantive even before every site is live. The countervailing risk is confusing the counterparty's reach with realized adoption while understating data preparation, support costs and central-payer concentration. ## Underwriting questions 1. How many sites are active, billable and collecting cash under the agreement? 2. What lawful reuse rights and clinical labels accompany the shared images? 3. What minimum volumes, acceptance conditions and cancellation terms govern rollout spending? ## Primary sources 1. [Lunit / issuer-distributed Salud Digna agreement announcement](https://www.prnewswire.com/news-releases/lunit-inks-partnership-with-salud-digna-to-advance-ai-in-medical-imaging-302316214.html) (2024-11-27) 2. [Lunit / complete FY2025 annual filing, consolidated financial context](https://kind.krx.co.kr/external/2026/03/23/002296/20260323009649/11011.htm) (2026-03-23)